COE Inhibits Vasculogenic Mimicry by Targeting EphA2 in Hepatocellular Carcinoma, a Research Based on Proteomics Analysis
New strategies and drugs are urgently needed to improve the treatment of hepatocellular carcinoma (HCC). Vasculogenic mimicry (VM) has been elucidated being associated with the progression of HCC and anti-VM could be a promising strategy. Celastrus orbiculatus extract (COE), a mixture of 26 compound...
Main Authors: | Zewen Chu, Xin Shi, Gaoyang Chen, Xuejun He, Yayun Qian, Haibo Wang, Li Tao, Yanqing Liu, Wei Jiang, Jue Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-03-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.619732/full |
Similar Items
-
Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors
by: Hatano Manabu, et al.
Published: (2004-11-01) -
EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer
by: Robiya Joseph, et al.
Published: (2024-01-01) -
EphA2 and EGFR: Friends in Life, Partners in Crime. Can EphA2 Be a Predictive Biomarker of Response to Anti-EGFR Agents?
by: Mario Cioce, et al.
Published: (2021-02-01) -
Inhibition of EphA2 by Dasatinib Suppresses Radiation-Induced Intestinal Injury
by: Areumnuri Kim, et al.
Published: (2020-11-01) -
Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer
by: Santosh K. Dasari, et al.
Published: (2023-02-01)